Full Breakdown
Bristol Myers Squibb and Hengrui Pharma Seal $15.2 Billion Early-Stage Drug Collaboration
5/13/2026, 4:19:34 AM
Deal Overview: Scope, Value, and Timeline
On 12 May 2026, U.S. biopharma giant Bristol Myers Squibb (BMS) and China’s Jiangsu Hengrui Pharmaceuticals announced a global collaboration and licensing agreement covering 13 early-stage programmes—four oncology/haematology candidates from Hengrui, four immunology candidates from BMS, and five jointly discovered assets. BMS will obtain worldwide rights to the four Hengrui assets outside mainland China, Hong Kong and Macau; Hengrui will receive exclusive rights to the four BMS assets in those territories. The deal’s potential total value is up to $15.2 billion, with an expected close in the third quarter of 2026.
Background: Growing China-U.S. Pharma Partnerships
Hengrui has become a frequent licensing partner for Western firms, previously striking a $12 billion deal with GSK and a $200 million agreement with Merck. The partnership reflects a broader trend of multinational drugmakers turning to Chinese pipelines for pre-clinical and early-clinical candidates, attracted by rapid proof-of-concept timelines and a deep pool of experimental compounds.
Key Players and Their Roles
- Bristol Myers Squibb – Princeton, New Jersey-based leader in oncology, immunology, and cardiovascular medicines.
- Jiangsu Hengrui Pharmaceuticals – China’s largest drugmaker by market capitalisation, headquartered in Jiangsu, with a portfolio focused on oncology, anti-infectives, surgery, and metabolic diseases.
- Robert Plenge – Chief Research Officer and Executive Vice President, BMS.
- Frank Jiang – Executive Vice President and Chief Strategy Officer, Hengrui.
Hengrui will lead early-clinical development and proof-of-concept work for all 13 programmes; BMS will retain global commercialization rights for the assets it licenses.
Financial Terms and Milestones
The agreement includes a $600 million upfront payment to Hengrui, followed by $175 million payments on the first (2027) and second (2028) anniversaries, bringing near-term consideration to $950 million. Additional milestone payments tied to development, regulatory approval, and commercial performance could lift the total to $15.2 billion. Hengrui will also receive tiered royalties on sales of partnered products outside its designated territory. Following the announcement, Hengrui shares rose ?8 % in Shanghai and 5.3 % in Hong Kong.
Strategic Rationale and Expected Impact
BMS seeks to replenish its pipeline amid looming patent expirations and to accelerate early-clinical learning by leveraging Hengrui’s discovery platform. Hengrui gains exposure to global markets, royalty streams, and validation of its R&D capabilities. Both firms aim to address unmet medical needs in oncology, haematology, and immunology while diversifying geographic risk.
Official Statements from BMS and Hengrui
Robert Plenge described the pact as a “strategic collaboration” that reinforces BMS’s “commitment to advancing innovative science while maintaining a disciplined approach to portfolio management.” Frank Jiang said the agreement “advances Hengrui’s objective to become a global biopharmaceutical leader” and “reflects a highly synergistic collaboration between two global innovators with complementary strengths.”
Criticism and Concerns Over Chinese Influence
Industry observers and some U.S. lawmakers have voiced alarm that increasing reliance on Chinese drug candidates could heighten geopolitical and supply-chain risks for American biotech firms. No regulatory actions have yet followed these concerns.
Conflicting Reports on Development Stage
Sources differ on the precise development status of the 13 programmes: several describe them as pre-clinical (no human trials), while others refer to early clinical development. The exact stage remains undisclosed.
Verbatim Quotes
- “This strategic collaboration reflects our commitment to advancing innovative science while maintaining a disciplined approach to portfolio management.” — Robert Plenge, Chief Research Officer & EVP, Bristol Myers Squibb
- “By leveraging complementary capabilities across geographies, we aim to accelerate early clinical learning and make informed decisions that support driving top tier growth in the next decade and, ultimately, our mission to deliver medicines that help patients prevail over serious diseases.” — Robert Plenge, BMS
- “ “This broad strategic collaboration reflects a highly synergistic collaboration between two global innovators with complementary strengths.” — Frank Jiang, Executive Vice President & Chief Strategy Officer, Jiangsu Hengrui Pharmaceuticals
- “By leveraging Hengrui’s growing R&D capabilities and proven efficiency in discovering and advancing innovative therapies, we are poised to advance the best of both pipelines,” — Frank Jiang, Hengrui
Future Steps and Closing Timeline
The partnership is slated to close in Q3 2026 pending antitrust and financial-regulatory approvals. After closing, joint development will commence, with milestone-triggered payments scheduled through 2028 and beyond, contingent on successful progression of the 13 assets.
